SkyePharma Plc, which develops technologies for delivering drugs, essentially broke even in 2008 before exceptional items and expects to be well off in the future provided its pending US application for an asthma drug is approved, the UK company’s directors said in their annual report and during a meeting with analysts on 26 March 2009.
